{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:09Z","timestamp":1787772369930,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chronic idiopathic urticaria (CIU) is a chronic relapsing disease with hives for a period of six weeks or more. It has a significant impact on the physical and mental well-being of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives:<\/jats:title>\n                    <jats:p>Open-label non-blinded study of over 600 patients diagnosed with CIU was done. The aim of the study was to observe the following: 1. Characteristics of patients of anti-histaminic resistant CIU, 2. Efficacy of cyclosporin and any adverse events in the study population and 3. Prognosis and relapse rates of these patients at the end of one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Detailed history taking and guided clinical evaluation were done to include chronic resistant urticarias in the study and their clinical characteristics and prognosis were studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 610 patients were diagnosed with CIU over a period of four years. Of these, 47 patients (7.7%) were diagnosed with anti-histaminic resistant urticaria. Of these, 30 patients (4.9%) who took treatment with cyclosporin at the above dosages were included in group 1. Rest 17 patients were in group 2 that were continued on anti-histaminics. Patients in cyclosporin group 1 showed a significant reduction in symptom scores as compared with group 2 at the end of six months. A lower need for corticosteroid therapy was noted in the cyclosporin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cyclosporin in low doses is very useful in anti-histaminic resistant urticaria with the duration of therapy being six months. It is cost-effective in low and medium-income countries and easily available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_718_21","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:14:59Z","timestamp":1716984899000},"page":"518-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Open-label Non-blinded Cohort study on Anti-Histaminic Resistant Chronic Idiopathic Urticaria in Western India"],"prefix":"10.4103","volume":"67","author":[{"given":"Subramanian","family":"Natarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20240829","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"R2-6-20240829","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"R3-6-20240829","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R4-6-20240829","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: A meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R6-6-20240829","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/ijd.IJD_308_17","article-title":"Consensus statement for the diagnosis and treatment of urticaria: A 2017 update","volume":"63","author":"Godse","year":"2018","journal-title":"Indian J Dermatol"},{"key":"R7-6-20240829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/0019-5154.41662","article-title":"Cyclosporine in chronic idiopathic urticaria with positive autologous serum skin test","volume":"53","author":"Godse","year":"2008","journal-title":"Indian J Dermatol"},{"key":"R8-6-20240829","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1398-9995.2010.02419.x","article-title":"Cyclosporine-A in severe chronic urticaria: The option for long-term therapy","volume":"65","author":"Kessel","year":"2010","journal-title":"Allergy"},{"key":"R9-6-20240829","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2011.08.013","article-title":"Factors that predict the success of cyclosporine treatment for chronic urticaria","volume":"107","author":"Hollander","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R10-6-20240829","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2340\/00015555-0939","article-title":"Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up","volume":"91","author":"Boubouka","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R11-6-20240829","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaip.2014.04.011","article-title":"Treatment of chronic urticaria in children with antihistamines and cyclosporine","volume":"2","author":"Neverman","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R12-6-20240829","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial","volume":"55","author":"Vena","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_718_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:41:30Z","timestamp":1787769690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_718_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_718_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}